Current Surgical is a private, pre-revenue medical device startup founded in 2016, building a foundational platform for the next generation of minimally invasive, digital surgery. Its core technology integrates AI-processed real-time imaging with precision focused ultrasound ablation in a closed-loop control system, initially targeting early-stage solid tumor ablation. The company has a clear multi-year pipeline to expand into cardiac, pain, and neurological markets, is backed by elite investors like True Ventures, and has secured non-dilutive funding from the NIH and NSF to advance its platform.
OncologyCardiologyNeurologyPain Management
Technology Platform
Integrated digital surgery platform combining AI-processed real-time ultrasound imaging, precision focused ultrasound ablation, and closed-loop automated control.
Funding History
2
Total raised:$15M
Series A$12MKhosla Ventures
Seed$3MY Combinator
Opportunities
The platform's foundational nature allows sequential entry into multiple multi-billion dollar surgical markets (cardiac, pain, neurology) beyond the initial oncology focus, creating a massive total addressable market.
The shift towards value-based care and minimally invasive procedures creates strong tailwinds for a technology that promises improved outcomes, consistency, and potentially lower costs.
Risk Factors
The company faces significant technical integration risks in creating a reliable, automated closed-loop surgical system, and must navigate a complex FDA regulatory pathway for a novel device.
It will also need to displace entrenched competitors in each target market by proving clear clinical and economic superiority to drive surgeon adoption.
Competitive Landscape
Current Surgical competes in distinct but overlapping segments. In tumor ablation, competitors include Medtronic (HVIF), Boston Scientific, and AngioDynamics. In cardiac ablation, giants like Abbott and Medtronic dominate. Its unique differentiator is the fully integrated, AI-driven, closed-loop platform combining real-time visualization and treatment, a approach not yet commercialized by established players.
